Oncolytics open enrollment for Phase II trial of Reolysin

Candian firm Oncolytics Biotech has started patient enrollment in a UK Phase II clinical trial of Reolysin (human reovirus) in people with advanced head and neck cancers.

The trial is a 14-patient, single-arm, open-label, dose-targeted, non-randomized study of the drug given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible subjects include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective is to measure tumor responses and their duration, as well as to describe any evidence of antitumor activity. The secondary objective is to determine the safety and tolerability of Reolysin.